[CAS NO. 60628-96-8] Bifonazole
PRODUCTS SPECIFICATIONS [60628-96-8]
DESCRIPTION [60628-96-8]
Overview
| MDL | MFCD00865567 |
|---|---|
| Molecular Weight | 310.39 |
| Molecular Formula | C22H18N2 |
| SMILES | N1(C(C2=CC=C(C3=CC=CC=C3)C=C2)C4=CC=CC=C4)C=CN=C1 |
Summary
Bifonazole (Bay H-4502) is an imidazole antifungal drug.
IC50 & Target
Antifungal [1] .
In Vitro
Bifonazole (Bay H-4502), a new broad-spectrum antimycotic, interferes with sterol biosynthesis. In dermatophytes bifonazole additionally inhibits directly HMG-CoA-reductase. bifonazole possesses a sequential mode of action, namely inhibition of cytochrome P450-dependent C14-demethylation of sterols and direct inhibition of HMG-CoA-reductase. In vitro Bifonazole (Bay H-4502) shows a strongly pH-dependent efficacy. The uptake kinetics of Bifonazole (Bay H-4502) have been measured with different pathogens [1] . Bifonazole (Bay H-4502) additionally leads to a generally decreased rate of sterol biosynthesis as compared to clotrimazole, due to a direct inhibition of microsomal HMG-CoA-reductase. The additional fungicidal effects of Bifonazole (Bay H-4502) are considered to originate from a sequential action by inhibition of HMG-CoA-reductase and of cytochrome P450 [2] . Bifonazole (Bay H-4502) were affected by choice of medium with Kimmig's agar generally giving the lowest MIC's. Bifonazole MICs were shown to vary with pH (maximal activity at pH 6.5) with selected yeasts when tested on Kimmig's agar [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02705664 | Galderma R&D |
Foot Dermatoses
|
January 2016 | Phase 4 |
| NCT00781820 | Bayer |
Onychomycosis
|
October 2008 | Phase 3 |
| NCT01013909 | Bayer |
Tinea Pedis
|
December 2009 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 33.33 mg/mL ( 107.38 mM ; Need ultrasonic)
H 2 O : 0.67 mg/mL ( 2.16 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.2218 mL | 16.1088 mL | 32.2175 mL |
| 5 mM | 0.6444 mL | 3.2218 mL | 6.4435 mL |
| 10 mM | 0.3222 mL | 1.6109 mL | 3.2218 mL |
References
- [1] Berg, D. and M. Plempel, Bifonazole, a biochemist's view. Dermatologica, 1984. 169 Suppl 1: p. 3-9.
- [2] Berg, D., et al., Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. Arzneimittelforschung, 1984. 34(2): p. 139-46.
- [3] Shadomy, S., D.M. Dixon, and R. May, A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia, 1982. 20(4): p. 313-23.
Synonyms